RhumbLine Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.3M | Sell |
163,018
-1,524
| -0.9% | -$334K | 0.03% | 481 |
|
|
2026
Q1 | $31.1M | Buy |
164,542
+6,308
| +4% | +$1.1M | 0.03% | 532 |
|
|
2025
Q4 | $26.9M | Sell |
158,234
-6,427
| -4% | -$985K | 0.02% | 589 |
|
|
2025
Q3 | $21.7M | Sell |
164,661
-351
| -0.2% | -$42.1K | 0.02% | 687 |
|
|
2025
Q2 | $17.5M | Buy |
165,012
+456
| +0.3% | +$49.5K | 0.02% | 778 |
|
|
2025
Q1 | $20.4M | Sell |
164,556
-3,004
| -2% | -$392K | 0.02% | 680 |
|
|
2024
Q4 | $20.6M | Buy |
167,560
+1,755
| +1% | +$207K | 0.02% | 680 |
|
|
2024
Q3 | $18.5M | Sell |
165,805
-3,595
| -2% | -$394K | 0.02% | 758 |
|
|
2024
Q2 | $18.1M | Sell |
169,400
-15,597
| -8% | -$1.71M | 0.02% | 725 |
|
|
2024
Q1 | $22.3M | Sell |
184,997
-783
| -0.4% | -$95.9K | 0.02% | 646 |
|
|
2023
Q4 | $22.9M | Sell |
185,780
-2,209
| -1% | -$276K | 0.02% | 604 |
|
|
2023
Q3 | $24.3M | Sell |
187,989
-1,676
| -0.9% | -$223K | 0.03% | 536 |
|
|
2023
Q2 | $23.5M | Buy |
189,665
+7,190
| +4% | +$967K | 0.03% | 565 |
|
|
2023
Q1 | $26.7M | Buy |
182,475
+1,448
| +0.8% | +$214K | 0.03% | 476 |
|
|
2022
Q4 | $28.8M | Buy |
181,027
+370
| +0.2% | +$54.2K | 0.04% | 422 |
|
|
2022
Q3 | $24.1M | Buy |
180,657
+4,006
| +2% | +$609K | 0.04% | 458 |
|
|
2022
Q2 | $27.6M | Buy |
176,651
+14,465
| +9% | +$2.23M | 0.04% | 399 |
|
|
2022
Q1 | $25.2M | Sell |
162,186
-729
| -0.4% | -$106K | 0.03% | 476 |
|
|
2021
Q4 | $20.8M | Buy |
162,915
+9,591
| +6% | +$1.26M | 0.03% | 597 |
|
|
2021
Q3 | $20M | Sell |
153,324
-4,101
| -3% | -$620K | 0.03% | 590 |
|
|
2021
Q2 | $28M | Buy |
157,425
+7,590
| +5% | +$1.31M | 0.04% | 443 |
|
|
2021
Q1 | $24.6M | Sell |
149,835
-860
| -0.6% | -$142K | 0.03% | 494 |
|
|
2020
Q4 | $24.9M | Sell |
150,695
-9,970
| -6% | -$1.48M | 0.03% | 462 |
|
|
2020
Q3 | $22.9M | Buy |
160,665
+85,444
| +114% | +$10.6M | 0.04% | 427 |
|
|
2020
Q2 | $8.3M | Buy |
75,221
+2,563
| +4% | +$283K | 0.01% | 873 |
|
|
2020
Q1 | $7.25M | Buy |
72,658
+7,051
| +11% | +$912K | 0.02% | 817 |
|
|
2019
Q4 | $9.79M | Buy |
65,607
+1,539
| +2% | +$209K | 0.02% | 844 |
|
|
2019
Q3 | $8.21M | Buy |
64,068
+17
| +0% | +$2.28K | 0.02% | 890 |
|
|
2019
Q2 | $9.13M | Buy |
64,051
+6,499
| +11% | +$873K | 0.02% | 824 |
|
|
2019
Q1 | $8.23M | Buy |
57,552
+49
| +0.1% | +$6.39K | 0.02% | 880 |
|
|
2018
Q4 | $7.13M | Sell |
57,503
-2,763
| -5% | -$410K | 0.02% | 887 |
|
|
2018
Q3 | $10.1M | Sell |
60,266
-1,126
| -2% | -$194K | 0.02% | 673 |
|
|
2018
Q2 | $10.6M | Buy |
+61,392
| New | +$10M | 0.02% | 655 |
|
|
2016
Q2 | – | Sell |
-52,950
| Closed | -$6.91M | – | 3003 |
|
|
2016
Q1 | $6.91M | Sell |
52,950
-325
| -0.6% | -$40.5K | 0.02% | 685 |
|
|
2015
Q4 | $7.49M | Buy |
53,275
+674
| +1% | +$93.4K | 0.02% | 634 |
|
|
2015
Q3 | $6.99M | Buy |
52,601
+2,537
| +5% | +$437K | 0.02% | 652 |
|
|
2015
Q2 | $8.81M | Buy |
50,064
+4,087
| +9% | +$734K | 0.03% | 567 |
|
|
2015
Q1 | $7.94M | Buy |
45,977
+1,736
| +4% | +$298K | 0.02% | 615 |
|
|
2014
Q4 | $7.24M | Sell |
44,241
-1,170
| -3% | -$194K | 0.02% | 619 |
|
|
2014
Q3 | $7.29M | Sell |
45,411
-2,358
| -5% | -$363K | 0.02% | 586 |
|
|
2014
Q2 | $7.02M | Buy |
47,769
+6,680
| +16% | +$926K | 0.02% | 635 |
|
|
2014
Q1 | $5.7M | Sell |
41,089
-1,934
| -4% | -$291K | 0.02% | 758 |
|
|
2013
Q4 | $5.45M | Sell |
43,023
-2,844
| -6% | -$294K | 0.02% | 776 |
|
|
2013
Q3 | $4.22M | Sell |
45,867
-7,243
| -14% | -$584K | 0.01% | 892 |
|
|
2013
Q2 | $3.65M | Buy |
+53,110
| New | +$3.25M | 0.01% | 935 |
|
Other funds holding JAZZ
RhumbLine Advisers's JAZZ Position: Q2 2026 in Review
RhumbLine Advisers reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.93% in Q2 2026, selling an estimated $334K and leaving 163,018 shares worth $39.3M. The position accounts for 0.03% of the portfolio, ranked #481.
RhumbLine Advisers first reported a position in JAZZ in Q2 2013 and has held it in 45 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- RhumbLine Advisers held 163,018 shares of Jazz Pharmaceuticals worth $39.3M as of Q2 2026.
- RhumbLine Advisers sold 1,524 Jazz Pharmaceuticals shares in Q2 2026, an estimated $334K.
- Jazz Pharmaceuticals made up 0.03% of RhumbLine Advisers's portfolio in Q2 2026, its #481 holding.
- RhumbLine Advisers first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.